Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (NYSE:DHR) has completed its acquisition of Masimo, a specialty diagnostics provider focused on pulse oximetry and AI-enabled patient monitoring. Masimo becomes a wholly-owned subsidiary, will operate as a stand-alone company within Danaher’s Diagnostics segment, and its common stock has stopped trading on Nasdaq.
Danaher keeps previously communicated Q2 and full-year 2026 guidance ranges, excluding Masimo. The company does not expect a material Masimo contribution in Q2 2026 and plans to update full-year 2026 guidance with its second-quarter earnings release.
Sirius XM Holdings (NASD: SIRI) will join the S&P MidCap 400, replacing Masimo (NASD: MASI), effective before the market opens on June 11, 2026. Danaher (NYSE: DHR), an S&P 500 and 100 constituent, is acquiring Masimo, with the deal expected to close after final conditions.
On June 11, 2026, Sirius XM will be added to the index as a Communication Services company, while Masimo will be removed from the index’s Health Care sector.
SCIEX (NYSE:DHR) launched the novus V55 triple quadrupole mass spectrometer at ASMS, paired with SCIEX OS 5.0 and new AI tools. The system targets high-throughput labs across food, pesticide, pharmaceutical impurity, bioanalysis and PFAS testing.
Key features include aeMRM acquisition up to 1,000 MRMs/second, a 35% smaller footprint, and about 40% lower energy and cooling needs versus the SCIEX 5500+ system, plus centralized monitoring, reporting and AI-enabled workflow support.
SCIEX, part of Danaher (NYSE:DHR), announced platform-wide upgrades to its accurate mass ZenoTOF line at ASMS 2026. Enhancements center on new SCIEX OS 5.0 software, expanded front-end compatibility, and collaborations across leading proteomics and metabolomics software platforms.
SCIEX OS 5.0 adds Central Metrics Tracker, Central Monitoring, Reporter Template Creator, and AI-enabled “helpme” and Calculated Columns. ZT Scan DIA 3.0, Echo MS+ integration, HDX-MS automation, new source options, and partnerships with PEAKS, MS-Dial, and mzmine aim to streamline omics workflows.
Henry Schein (Nasdaq: HSIC) elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus.
Daniel brings decades of healthcare and industrial leadership, including 14 years as Executive Vice President at Danaher (NYSE: DHR) overseeing multiple segments, such as its dental portfolio, and board service at Envista (NYSE: NVST). Company leadership highlighted his understanding of Henry Schein’s business and markets as important for advancing its long-term strategy and integrated healthcare solutions platform.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas on May 13, 2026 at 11:20 a.m. PT. The presentation will be simultaneously webcast on www.danaher.com.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.40 per share, payable on July 31, 2026 to shareholders of record on June 26, 2026.
The Board of Directors approved the dividend on May 5, 2026.
Masimo (Nasdaq: MASI) shareholders approved the merger agreement with Danaher (NYSE: DHR) at a special meeting held May 1, 2026. Under the agreement, each Masimo share will be converted into $180.00 in cash at closing. The merger remains subject to customary closing conditions, including required regulatory approvals and clearances. Masimo expects the transaction to close in 2026 and to operate as an independent operating company within Danaher’s Diagnostics segment.
CD&R announced that Jim Lico, former President and CEO of Fortive, has been engaged as an Operating Advisor to CD&R funds effective April 28, 2026. Lico will support the Firm’s industrials team on sourcing investments and advising portfolio industrial businesses. He led Fortive from 2016–2025, helping grow market capitalization from $16B to $25B and delivering annual revenues above $6B. Lico serves on the boards of DuPont (DD) and PTC and brings nearly three decades of industrial and operational experience.
Danaher (NYSE: DHR) priced a €3.0 billion senior notes offering with four tranches due 2028, 2030, 2034 and 2038.
Net proceeds are estimated at approximately €2.98 billion, intended primarily to pay a portion of the cash consideration and certain costs for the acquisition of Masimo, with closing expected April 29, 2026.